BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis Christopher Carter, LiYa Tang, et al. Cancer Res 2004;64:7099-7109
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro:induction of apoptosis through Akt and c-Jun NH 2-terminal kinase pathways Bret B. Friday, Jin-Ping Lai, et al. Mol Cancer Ther 2006;5:2378-2387
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.